← Leaderboards
Daohong Zhou
Medical University Of South Carolina
$16,846,361
Attributed
$23,709,375
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,709,375 · 16
By mechanism
R01$21,704,592 · 11
P20$1,344,055 · 1
P30$432,157 · 2
R29$210,571 · 1
R13$18,000 · 1
Top collaborators
- Guangrong Zheng22 shared
- Marina Y Konopleva7 shared
- Jennifer Hartt Elisseeff5 shared
- Jose G. Trevino5 shared
- Weizhou Zhang5 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Yusuf Awni Hannun$36,962,745
- Yan Huang$5,705,032
- Lina M Obeid$14,979,081
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseCellsIonizing RadiationMediatingMouse ModelLeadSenescenceToxic EffectApoptosisHematopoietic Stem CellsChemotherapyIn VivoCancer TherapyPreventIn VitroInhibitor/AntagonistPlayTechnologyDoseCell AgingBone MarrowInjuryMalignant NeoplasmsInnovation
Grant awards (89)
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$514,305
R01 · FY2025 · CA
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$486,504
R01 · FY2024 · CA
Inhibition of Bcl-xL by Targeted Degradation$480,430
R01 · FY2024 · CA
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer$515,151
R01 · FY2023 · CA
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$501,347
R01 · FY2023 · AG
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$497,648
R01 · FY2023 · CA
Inhibition of Bcl-xL by Targeted Degradation$495,601
R01 · FY2023 · CA
Inhibition of Bcl-xL by Targeted Degradation$72,810
R01 · FY2023 · CA
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer$515,151
R01 · FY2022 · CA
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$503,572
R01 · FY2022 · AG
Inhibition of Bcl-xL by Targeted Degradation$495,601
R01 · FY2022 · CA
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$493,605
R01 · FY2022 · CA
Mays Cancer Center at UT Health SA$90,667
P30 · FY2022 · CA · contact PI
Chaperone-Mediated Protein Degradation of Bcl-xL and Bcl-2$46,984
R01 · FY2022 · CA
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer$525,664
R01 · FY2021 · CA
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$505,755
R01 · FY2021 · AG · contact PI
Inhibition of Bcl-xL by Targeted Degradation$505,715
R01 · FY2021 · CA
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasis$500,180
R01 · FY2021 · CA
Ionizing radiation induced hematological malignancies$272,477
R01 · FY2021 · CA · contact PI
Role of Senescent Cells in Radiation-induced Pulmonary Fibrosis$192,085
R01 · FY2021 · CA · contact PI
Role of Senescent Cells in Radiation-induced Pulmonary Fibrosis$175,807
R01 · FY2021 · CA · contact PI
Ionizing radiation induced hematological malignancies$78,102
R01 · FY2021 · CA · contact PI
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer$525,664
R01 · FY2020 · CA · contact PI
Inhibition of Bcl-xL by Targeted Degradation$518,840
R01 · FY2020 · CA
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$507,895
R01 · FY2020 · AG · contact PI
Role of Senescent Cells in Radiation-induced Pulmonary Fibrosis$376,673
R01 · FY2020 · CA · contact PI
Ionizing radiation induced hematological malignancies$353,050
R01 · FY2020 · CA · contact PI
Develop BCL-xL proteolysis targeting chimeras as safer and better senolytics$560,435
R01 · FY2019 · AG · contact PI
Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer$525,664
R01 · FY2019 · CA · contact PI
Role of Senescent Cells in Radiation-induced Pulmonary Fibrosis$365,372
R01 · FY2019 · CA · contact PI
Ionizing radiation induced hematological malignancies$345,092
R01 · FY2019 · CA · contact PI
Cellular and Molecular Analytic Core$268,812
P20 · FY2019 · GM · contact PI
Ionizing radiation induced hematological malignancies$368,866
R01 · FY2018 · CA · contact PI
Role of Senescent Cells in Radiation-induced Pulmonary Fibrosis$363,042
R01 · FY2018 · CA · contact PI
Cancer Therapy-induced Long-term Bone Marrow Injury$308,813
R01 · FY2018 · CA · contact PI
Cellular and Molecular Analytic Core$268,810
P20 · FY2018 · GM · contact PI
The 4th International Cell Senescence Association (ICSA) meeting (ICSA 2018)- Resubmission$18,000
R13 · FY2018 · AG · contact PI
Ionizing radiation induced hematological malignancies$355,340
R01 · FY2017 · CA · contact PI
Role of Senescent Cells in Radiation-induced Pulmonary Fibrosis$354,709
R01 · FY2017 · CA · contact PI
Cancer Therapy-induced Long-term Bone Marrow Injury$301,725
R01 · FY2017 · CA · contact PI
Cellular and Molecular Analytic Core$268,811
P20 · FY2017 · GM · contact PI
Cancer Therapy-induced Long-term Bone Marrow Injury$301,725
R01 · FY2016 · CA · contact PI
Cellular and Molecular Analytic Core$268,811
P20 · FY2016 · GM · contact PI
Cancer Therapy-induced Long-term Bone Marrow Injury$301,725
R01 · FY2015 · CA · contact PI
Cellular and Molecular Analytic Core$268,811
P20 · FY2015 · GM · contact PI
Cancer Therapy-induced Long-term Bone Marrow Injury$301,725
R01 · FY2014 · CA · contact PI
Flow Cytometry & Cell Sorting$86,184
P30 · FY2013 · CA · contact PI
Flow Cytometry & Cell Sorting$3,093
P30 · FY2013 · CA · contact PI
Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury$342,278
R01 · FY2012 · AI · contact PI
Flow Cytometry & Cell Sorting$54,231
P30 · FY2012 · CA · contact PI
Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury$342,657
R01 · FY2011 · AI · contact PI
Cancer therapy-induced long-term bone marrow injury$267,235
R01 · FY2011 · CA · contact PI
Radiation-induced lymphoid and hematopoietic toxicity$142,415
R01 · FY2011 · CA · contact PI
Flow Cytometry & Cell Sorting$58,192
P30 · FY2011 · CA · contact PI
Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury$351,557
R01 · FY2010 · AI · contact PI
Cancer therapy-induced long-term bone marrow injury$275,500
R01 · FY2010 · CA · contact PI
Cancer therapy-induced long-term bone marrow injury$185,637
R01 · FY2010 · CA · contact PI
Radiation-induced lymphoid and hematopoietic toxicity$130,500
R01 · FY2010 · CA · contact PI
Flow Cytometry & Cell Sorting$72,306
P30 · FY2010 · CA · contact PI
Radiation-induced lymphoid and hematopoietic toxicity$17,432
R01 · FY2010 · CA · contact PI
Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury$360,866
R01 · FY2009 · AI · contact PI
Cancer therapy-induced long-term bone marrow injury$277,400
R01 · FY2009 · CA · contact PI
Radiation-induced lymphoid and hematopoietic toxicity$147,832
R01 · FY2009 · CA · contact PI
Flow Cytometry & Cell Sorting$67,484
P30 · FY2009 · CA · contact PI
Cancer therapy-induced long-term bone marrow injury$57,990
R01 · FY2009 · CA · contact PI
Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury$24,550
R01 · FY2009 · AI · contact PI
Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury$6,071
R01 · FY2009 · AI · contact PI
Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury$1,662
R01 · FY2009 · AI · contact PI
Role of p38 MAPK in HSC Self-Renewal and Radiation-Induced Bone Marrow Injury$368,750
R01 · FY2008 · AI · contact PI
Cancer therapy-induced long-term bone marrow injury$277,400
R01 · FY2008 · CA · contact PI
Radiation-induced lymphoid and hematopoietic toxicity$147,832
R01 · FY2008 · CA · contact PI
Cancer therapy-induced long-term bone marrow injury$277,400
R01 · FY2007 · CA · contact PI
D609-A novel cytoprotectant & selective antitumor agent$244,324
R01 · FY2007 · CA · contact PI
Radiation-induced lymphoid and hematopoietic toxicity$147,832
R01 · FY2007 · CA · contact PI
D609-A novel cytoprotectant & selective antitumor agent$251,621
R01 · FY2006 · CA · contact PI
D609-A novel cytoprotectant &selective antitumor agent$257,677
R01 · FY2005 · CA
D609-A novel cytoprotectant &selective antitumor agent$269,177
R01 · FY2004 · CA
PROPHYLAXIS OF GVHD BY INHIBITING IR INDUCED NFKB$181,731
R01 · FY2003 · CA
PROPHYLAXIS OF GVHD BY INHIBITING IR INDUCED NFKB$182,060
R01 · FY2002 · CA
RADIATION-INDUCED LYMPHOID AND HEMATOPOIETIC TOXICITY$138,193
R01 · FY2002 · CA
PROPHYLAXIS OF GVHD BY INHIBITING IR INDUCED NFKB$186,538
R01 · FY2001 · CA
RADIATION-INDUCED LYMPHOID AND HEMATOPOIETIC TOXICITY$121,550
R01 · FY2001 · CA
RADIATION-INDUCED LYMPHOID AND HEMATOPOIETIC TOXICITY$111,085
R01 · FY2001 · CA
STRESSOR INDUCED MODULATION OF INDUCIBLE NO PRODUCTION$106,066
R29 · FY2001 · MH
PROPHYLAXIS OF GVHD BY INHIBITING IR INDUCED NFKB$150,509
R01 · FY2000 · CA
STRESSOR INDUCED MODULATION OF INDUCIBLE NO PRODUCTION$59,443
R29 · FY2000 · MH
STRESSOR INDUCED MODULATION OF INDUCIBLE NO PRODUCTION$45,062
R29 · FY2000 · MH
PROPHYLAXIS OF GVHD BY INHIBITING IR INDUCED NFKB$40,727
R01 · FY2000 · CA
RADIATION-INDUCED LYMPHOID AND HEMATOPOIETIC TOXICITY$7,755
R01 · FY2000 · CA